Alnylam presents results from KARDIA-1 Phase 2 dose-ranging study of Zilebesiran

Alnylam Pharmaceuticals announced results from the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen in development for the treatment of patients with hypertension and high cardiovascular risk. The study results were presented during the American Heart Association Scientific Sessions being held in Philadelphia, Pennsylvania from November 11-13, 2023. The KARDIA-1 study achieved its primary endpoint, with single doses of zilebesiran demonstrating clinically significant reductions in 24-hour mean systolic blood pressure measured by ambulatory blood pressure monitoring at Month 3 across all doses, with the 150 mg, 300 mg, and 600 mg doses achieving placebo-adjusted reductions of 14.1 mmHg, 16.7 mmHg, and 15.7 mmHg, respectively. The study also met key secondary endpoints across all doses, including demonstration of durable efficacy out to 6 months. At the 150 mg Q6M, 300 mg Q6M, 300 mg Q3M, and 600 mg Q6M doses, zilebesiran showed placebo-adjusted reductions in 24-hour mean SBP measured by ABPM of 11.1 mmHg, 14.5 mmHg, 14.1 mmHg, and 14.2 mmHg, respectively, at Month 6. Zilebesiran demonstrated an encouraging safety and tolerability profile that the company believes supports continued development.